KEAPSAKE

Phase 2 , Multicenter, Double-Blind Study of the Glutaminase Inhibitor Telaglenastat with Pembro and CTX Versus Placebo with Pembro and CTX in 1L, Metastatic KEAP1/NRF2-Mutated, Nonsquamous NSCLC

Targeted Disease(s):
Lung Cancer

Purpose of Study:

This is a randomized Phase 2 study that will test whether the investigational study drug called telaglenastat will be safe and potentially effective when combined with the FDA approved immunochemotherapy regimen of pembrolizumab, carboplatin, and pemetrexed in treating patients with stage IV lung cancer that has a mutation in NRF2/(NFE2L2) or KEAP1 genes. Patients on this study will not have received any systemic treatment for advanced lung cancer. All patients in this study will receive the approved recommended treatment regimen of pembrolizumab, carboplatin, and pemetrexed either with or without telaglenastat.

Study Dates:
February 1, 2020 - October 31, 2024

Type of Study:
Pre-Market

Study Design:
Controlled Design

Study Location:
Nationwide

Funding Source:
Calithera Biosciences

ClinicalTrails.gov Identifier:
NCT04265534

No upcoming events near you